News for 'Pepfar'

Indian pharma eyes US gains as $63.7 bn patent cliff nears

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

'Made in India' dominates US AIDS scheme

Indian drug companies have cornered an overwhelming majority of drug approvals under the US President's Emergency Plan for AIDS Relief.

Ranbaxy files three anti-Retoviral patents

America should listen harder to India

Silicon Valley can be replicated, but this will only be achieved so long as fresh talent is welcomed by both our countries - a move that will surely spark a billion ideas and discoveries.